Voxel SA

Voxel SA maintains a conservative capital structure with a debt-to-equity ratio of 0.45 and a current ratio of 1.4, indicating moderate liquidity risk. The company's liquidity position is supported by a free cash flow of 32,055,900 PLN, though its net cash position is negative after subtracting total debt. The company's return on equity of 24.1% and return on assets of 13.94% outperform the industry median for healthcare facilities, reflecting strong operational efficiency. Profitability metrics show Voxel SA generates a gross profit margin of 28.8% (167,945,400 PLN gross profit on 583,788,600 PLN revenue) and an operating margin of 22.8% (132,931,400 PLN operating income). These figures exceed the industry median for healthcare services, where operating margins typically range between 15-20%. The company's net income margin of 16.9% (98,533,900 PLN net income) further underscores its profitability strength. Geographically, Voxel SA is concentrated in Poland, with no disclosed international revenue streams. Segment-wise, the company operates in diagnostic imaging and IT systems for healthcare, though it does not provide granular revenue breakdowns by business line. This lack of segmentation detail limits visibility into growth drivers and risk concentrations. The company's revenue growth trajectory is not explicitly provided in the latest filings, but its capital expenditure of -75,821,400 PLN suggests a focus on cost optimization rather than expansion. Analysts have assigned a mean price target of 174.70 PLN, with a median of 174.70 PLN and a range from 157.20 PLN to 192.20 PLN. The mean recommendation of 2.00 (1=strong buy, 5=strong sell) indicates a generally positive outlook. Risk factors include moderate liquidity risk due to negative net cash after debt and a medium risk rating from liquidity stress tests. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. The company's capital structure remains stable, with no material adjustments applied to valuation multiples. Recent events include the sale of its stake in Centrum Diagnostyki i Terapii Onkologicznej Sp. z o.o. in 2012 and ongoing operations in diagnostic imaging and IT systems. No recent filings or transcripts indicate material changes in strategy or operations.